The Multinational Association of Supportive Care in Cancer (MASCC) shared on LinkedIn:
“New publication from our Antiemetics Study Group.”
Title: Olanzapine (10 mg vs 5 mg vs 2.5 mg) for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) — a systematic review and network meta-analysis
Authors: Ronald Chow, Daniel Zhang, Gregory W. Chai, Monica Yuen, Angel Lu, Victoria Fortuna, Sumeet Talwar, Gabriel Boldt, Michael Lock, Shing Fung Lee, Lawson Eng, Hirotoshi Iihara, Mary Louise Affronti, Mitsue Saito, Matti Aapro, Paul J. Hesketh, Florian Scotté, Christina H. Ruhlmann, Jennifer Leigh
To which Florian Scotté, Head of the Interdisciplinary Division of Patient Pathways (DIOPP) at Gustave Roussy Cancer Campus, added:
“Congrats Ron for providing that important systematic review about the olanzapine dose to use in chemotherapy induced nausea and vomiting prophylaxis. Congrats to the antiemetics study group.
Don’t forget to save June 2027 for The MASCC annual meeting in Rotterdam (Europe).”
Other articles about MASCC on OncoDaily.